Bio-Techne Beats Estimates on Strong Drug Dev Demand

Bio-Techne, a biotech firm, surpassed analyst expectations for revenue and profit during its second quarter. This success was primarily driven by strong demand for its products, which are critical in the drug development pipeline. The company's largest segment, protein sciences, saw a 2% increase in sales, contributing significantly to overall revenue.

CEO Kim Kelderman noted that double-digit growth in the large pharma market, a fourth consecutive quarter of this trend, combined with improving biotech performance and stabilization in academic customers, fueled the company's results. While sales in the diagnostics and genomics unit saw a slight decline, the overall performance indicates a positive trajectory for the company within the life sciences sector.